EUVIMEDEUVIMED entdecken
Crossref

Tanshinone IIA Liposomes Treat Doxorubicin-Induced Glomerulonephritis by Modulating the Microenvironment of Fibrotic Kidneys

Tingjun Dong, Ning Yang, Jian Qin, Chengcheng Zhao, Tingyu Gao, Hao Ma, Caili Zhu, Huan Xu iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00042 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Tingjun Dong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, School of Chemistry and Chemical Engineering, Liaoning Normal University, Dalian 116029, China. Hauptthemen laut MEDLINE: Doxorubicin, Liposomes, Abietanes, Fibrosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Natural Science Foundation of Liaoning Province, Department of Education of Liaoning Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal fibrosis plays a key role in the pathogenesis of chronic kidney disease (CKD), in which the persistent high expression of transforming growth factor β1 (TGF-β1) and α-smooth muscle actin (α-SMA) contributes to the progression of CKD to renal failure. In order to improve the solubility, bioavailability, and targeting of tanshinone IIA (Tan IIA), a novel targeting material, aminoethyl anisamide-polyethylene glycol-1,2-distearoyl-sn-glycero-3-phosphate ethanolamine (AEAA-PEG-DSPE, APD) modified Tan IIA liposomes (APD-Tan IIA-L) was constructed. An animal model of glomerulonephritis induced by doxorubicin in BALB/c mice was established. APD-Tan IIA-L significantly decreased blood urea nitrogen and serum creatinine (SCr), and the consequences of renal tissue oxidative stress indicators showed that APD-Tan IIA-L downregulated malondialdehyde, upregulated superoxide dismutase, catalase, and glutathione peroxidase. Masson's trichrome staining showed that the deposition of collagen in the APD-Tan IIA-L group decreased significantly. The pro-fibrotic factors (fibronectin, collagen I, TGF-β1, and α-SMA) and epithelial-mesenchymal transition marker (N-cadherin) were significantly inhibited by APD-Tan IIA-L. By improving the microenvironment of fibrotic kidneys, APD-Tan IIA-L attenuated TGF-β1-induced excessive proliferation of fibroblasts and alleviated oxidative stress damage to the kidney, providing a new strategy for the clinical treatment of renal fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DoxorubicinLiposomesAbietanesFibrosisMice, Inbred BALB CKidneyGlomerulonephritisAnimalsMiceMaleTransforming Growth Factor beta1Oxidative StressEpithelial-Mesenchymal TransitionDisease Models, AnimalRenal Insufficiency, Chronic

Stichwörter der Autor:innen

TGF-β1Tan IIAliposomerenal fibrosissigma1 receptor

Substanzen

DoxorubicinLiposomestanshinoneAbietanesTransforming Growth Factor beta1

Autor:innen und Institutionen

  • Department of Pharmacy, School of Chemistry and Chemical Engineering, Liaoning Normal University, Dalian 116029, China.

ORCID-Profile: Huan Xu

Förderung

  • Natural Science Foundation of Liaoning Province
  • Department of Education of Liaoning Province

Zitieren

APA

Dong, T., Yang, N., Qin, J., Zhao, C., Gao, T., Ma, H., Zhu, C., & Xu, H. (2024). Tanshinone IIA Liposomes Treat Doxorubicin-Induced Glomerulonephritis by Modulating the Microenvironment of Fibrotic Kidneys. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00042

Vancouver

Dong T, Yang N, Qin J, Zhao C, Gao T, Ma H, et al. Tanshinone IIA Liposomes Treat Doxorubicin-Induced Glomerulonephritis by Modulating the Microenvironment of Fibrotic Kidneys. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00042

BibTeX
@article{Dong2024,
  author = {Dong, Tingjun and Yang, Ning and Qin, Jian and Zhao, Chengcheng and Gao, Tingyu and Ma, Hao and Zhu, Caili and Xu, Huan},
  title = {Tanshinone IIA Liposomes Treat Doxorubicin-Induced Glomerulonephritis by Modulating the Microenvironment of Fibrotic Kidneys},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00042}
}
Kostenlos starten →